All In Biotech

Drug Trial Radar · NCT03997123

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC.

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 923 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

923

Actual

Start

Jun 25, 2019

Primary completion

Mar 16, 2026

Study completion Mar 16, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

Conditions

  • Triple Negative Breast Neoplasms

Interventions

  • CapivasertibDrug

    400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.

  • PaclitaxelDrug

    80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.

  • PlaceboDrug

    Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: The time from date of randomisation to the date of death due to any cause up to approximately 42 months

Locations

260 sites in 30 countries. Site status is shown where the registry gives one.

  • Research Site

    Whittier, California

  • Research Site

    Whittier, California

  • Research Site

    Fort Myers, Florida

  • Research Site

    Miami, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Westwood, Kansas

  • Research Site

    Silver Spring, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    Nyack, New York

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Harrisburg, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Fort Worth, Texas

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad Autonomade Buenos Aires, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Barretos, Brazil

  • Research Site

    Florianópolis, Brazil

  • Research Site

    Goiânia, Brazil

  • Research Site

    Londrina, Brazil

  • Research Site

    Natal, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São José do Rio Preto, Brazil

Showing 40 of 260 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.